Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3329498 | Critical Reviews in Oncology/Hematology | 2009 | 5 Pages |
Abstract
Shortening duration of chemotherapy-induced neutropenia may reduce risk of infection and aid subsequent chemotherapy delivery. Cycle 1 neutrophil recovery was evaluated in 59 elderly women with breast cancer receiving adjuvant FEC100 (5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2 and cyclophosphamide 500 mg/m2) and randomized to pegfilgrastim primary prophylaxis (PP) from cycle 1, or secondary prophylaxis (SP, i.e., subsequent to a neutropenic event [no G-CSF in cycle 1]). In cycle 1, grade 4 neutropenia occurred in 77% (PP; N = 30) and 72% (SP; N = 29). Duration of grade 3-4 neutropenia was shorter with pegfilgrastim than without. Mean absolute neutrophil count (ANC) recovered above 1.0 Ã 109/L by day 9 (pegfilgrastim) versus days 16-18 (without). At last observation (â¥day 14 ± 2), no PP patient had ANC <1.0 Ã 109/L versus approximately 25% of those receiving no pegfilgrastim. In conclusion, cycle 1 pegfilgrastim improved recovery from severe neutropenia in elderly breast cancer patients receiving adjuvant FEC100.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
W. Brugger, P. Bacon, S. Lawrinson, G. Romieu,